Isabelle Magalhaes
About me
Associate professor (Docent) in Immunology, Karolinska Institutet.
Since March 2024, Team leader, Karolinska Institutet, Dept. of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM).February 2023-February 2024, Team leader, Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology.
April 2019 - January 2023, Senior researcher, deputy group leader, Karolinska- Institutet, Dept. of Oncology Pathology.
April 2015 - March 2019, Assistant professor, Karolinska Institutet, Dept. of
- Oncology Pathology.
September 2013 - March 2015, Postdoctoral fellow, U1016 INSERM, Institut - Cochin, Dept. of Endocrinology, Metabolism and Diabetes (Paris, France).
September 2010 - August 2013, Researcher, Karolinska University Hospital - Huddinge &
- Karolinska Institutet, Dept. of Laboratory Medicine.
June 2009 - August 2010, Postdoctoral fellow, Karolinska Institutet, Dept. of Microbiology, Tumor and Cell Biology.
2005-2009, PhD in Immunobiology, Karolinska Institutet, Dept. of - Microbiology, Tumor and Cellular Biology.
Thesis title: “/CD8alpha/alpha+ T-cells and Immune Memory/”.
https://openarchive.ki.se/xmlui/bitstream/handle/10616/39450/thesis.pdf?sequence=1&
- isAllowed=y
2002, Master in Immunology (Diplôme d’études approfondies), Paris VII - University &
- Institut Pasteur (Paris, France).
2000, Bachelor in Cellular Biology and Physiology, Rennes II University (Rennes, France).
Research
My goal is to contribute to the improvement of chimeric antigen receptor
- (CAR) T cell therapy for the treatment of cancer. Our group is working on the
- development of mesothelin (MSLN) CAR T cell therapy for the treatment of
- ovarian cancer. A preclinical model of orthotopic ovarian cancer in mice has
- been established in our group, which allows to test /in vivo/ the antitumor
- efficacy of MSLN CAR T cells.
Recent publications:
Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, - Hassan M, Magalhaes I*, Mattsson J*. Tuned activation of MSLN-CAR T cells
induces superior antitumor responses in ovarian cancer models. [1]J - Immunother Cancer. 2023 Feb
- 11(2). doi: 10.1136/jitc-2022-005691.
Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand - H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial
ovarian cancer and its tumor microenvironment. [2]Semin Cancer Biol. 2022 - Nov
- 86(Pt 3):207-223. doi: 10.1016/j.semcancer.2022.03.027.
Schoutrop E, Renken S, Micallef Nilsson I, Hahn P, Poiret T, Kiessling R, - Wickström SL, Mattsson J, Magalhaes I. Trogocytosis and fratricide killing
impede MSLN-directed CAR T cell functionality. - [3]Oncoimmunology. 2022
- 11(1):2093426. doi: 10.1080/2162402X.2022.2093426.
Renken S, Nakajima T, Magalhaes I, Mattsson J, Lundqvist A, Arnér ESJ, - Kiessling R, Wickström SL. Targeting of Nrf2 improves antitumoral responses
by human NK cells, TIL and CAR T cells during oxidative stress. [4]J - Immunother Cancer. 2022 Jun
- 10(6). doi: 10.1136/jitc-2021-004458.
Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran - L, Carlson JW, Lehti K, Hassan M, Magalhaes I*, Mattsson
- J*. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. [5]Cancer
- Res. 2021 Jun 1
- 81(11):3022-3035. doi: 10.1158/0008-5472.CAN-20-2701.
Magalhaes I, Fernebro J, Abd Own S, Glaessgen D, Corvigno S, Remberger M, - Mattsson J, Dahlstrand H. Mesothelin Expression in Patients with High-Grade
- Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with
- CD11c+ Expression in Tumor. [6]Adv Ther. 2020 Dec
- 37(12):5023-5031. doi:
- 10.1007/s12325-020-01520-w.
[1] https://www.ncbi.nlm.nih.gov/pubmed/36746513/
[2] https://www.ncbi.nlm.nih.gov/pubmed/35395389/
[3] https://www.ncbi.nlm.nih.gov/pubmed/35898704/
[4] https://www.ncbi.nlm.nih.gov/pubmed/35738800/
[5] https://www.ncbi.nlm.nih.gov/pubmed/33795251/
[6] https://www.ncbi.nlm.nih.gov/pubmed/33052561/
Teaching
I organize since 2016 the /Antigen Presentation and T Cell Activation/
- doctoral course (Karolinska Institutet #5739).
jsessionid=ea1cfadf091f0f25e85a4163cf3d">https://kiwas.ki.se/katalog/katalog/kurs/9195
Articles
- Journal article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2024;73(9):163
- Article: JOURNAL OF TRANSLATIONAL MEDICINE. 2024;22(1):273
- Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023;11(2):e005691
- Article: ONCOIMMUNOLOGY. 2022;11(1):2093426
- Article: SEMINARS IN CANCER BIOLOGY. 2022;86(Pt 3):207-223
- Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458
- Article: CANCER RESEARCH. 2021;81(11):3022-3035
- Article: ADVANCES IN THERAPY. 2020;37(12):5023-5031
- Article: FRONTIERS IN IMMUNOLOGY. 2019;10:1300
- Article: ONCOIMMUNOLOGY. 2019;8(2):e1535730
- Article: CYTOTHERAPY. 2018;20(7):941-951
- Article: JOURNAL OF IMMUNOTHERAPY. 2018;41(2):73-83
- Article: CLINICAL TRANSPLANTATION. 2017;31(8)
- Article: SCIENTIFIC REPORTS. 2017;7(1):6123
- Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2017;59:29-36
- Article: JOURNAL OF IMMUNOTHERAPY. 2017;40(4):132-139
- Article: FRONTIERS IN IMMUNOLOGY. 2017;8:1861
- Article: ONCOTARGET. 2016;7(46):74686-74700
- Article: IMMUNOLOGY. 2015;145(3):357-366
- Article: TRANSPLANT INFECTIOUS DISEASE. 2015;17(3):371-379
- Article: JOURNAL OF CLINICAL INVESTIGATION. 2015;125(4):1752-1762
- Article: FRONTIERS IN IMMUNOLOGY. 2015;6:341-7
- Article: JOURNAL OF IMMUNOTHERAPY. 2014;37(8):416-425
- Article: BMC IMMUNOLOGY. 2014;15:25
- Article: BMC INFECTIOUS DISEASES. 2014;14:319
- Article: JOURNAL OF IMMUNOTHERAPY. 2013;36(8):432-441
- Article: THORAX. 2013;68(3):269-276
- Article: JOURNAL OF INFECTIOUS DISEASES. 2012;205:S301-S315
- Article: MOLECULAR MEDICINE. 2012;18(4):647-658
- Article: BMC INFECTIOUS DISEASES. 2012;12:41
- Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 2):247-258
- Article: GENES AND IMMUNITY. 2011;12(7):513-522
- Article: IMMUNOLOGY. 2010;131(1):128-140
- Article: CLINICAL AND VACCINE IMMUNOLOGY. 2009;16(4):567-573
- Article: GENES AND IMMUNITY. 2009;10(2):132-140
- Article: JOURNAL OF IMMUNOTHERAPY. 2008;31(9):840-848
- Article: VIRUS RESEARCH. 2008;131(1):106-110
- Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(7):1512-1519
- Show more
All other publications
- Preprint: BIORXIV. 2024
- Review: METHODS IN MOLECULAR BIOLOGY. 2020;2098:3-21
- Review: EXPERT OPINION ON BIOLOGICAL THERAPY. 2019;19(8):811-827
- Review: IMMUNOTHERAPY. 2019;11(4):335-345
- Review: FRONTIERS IN IMMUNOLOGY. 2019;10:2309
- Review: EXPERT OPINION ON BIOLOGICAL THERAPY. 2017;17(6):691-699
- Other: MEDECINE/SCIENCES. 2015;31(8-9):717-719
- Letter: TRANSPLANTATION. 2014;98(12):E95-E96
- Review: CURRENT OPINION IN IMMUNOLOGY. 2014;27:83-88
- Other: EUROPEAN JOURNAL OF IMMUNOLOGY. 2010;40(5):1228-1231
- Thesis / dissertation: 2009
- Meeting abstract: CLINICAL IMMUNOLOGY. 2006;119:S116-S117
- Meeting abstract: JOURNAL OF IMMUNOTHERAPY. 2005;28(6):632
- Meeting abstract: JOURNAL OF IMMUNOTHERAPY. 2005;28(6):626-627
Employments
- Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2026
Degrees and Education
- Docent, Karolinska Institutet, 2021
- Degree Of Doctor Of Philosophy, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2009